loading
Kura Oncology Inc stock is traded at $7.65, with a volume of 2.56M. It is up +2.82% in the last 24 hours and up +14.69% over the past month. Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
See More
Previous Close:
$7.44
Open:
$7.43
24h Volume:
2.56M
Relative Volume:
1.84
Market Cap:
$664.00M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-3.5253
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
+4.22%
1M Performance:
+14.69%
6M Performance:
-7.27%
1Y Performance:
-61.25%
1-Day Range:
Value
$7.40
$7.80
1-Week Range:
Value
$6.95
$7.80
52-Week Range:
Value
$5.41
$21.57

Kura Oncology Inc Stock (KURA) Company Profile

Name
Name
Kura Oncology Inc
Name
Phone
(858) 500-8800
Name
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Name
Employee
192
Name
Twitter
@kuraoncology
Name
Next Earnings Date
2025-02-21
Name
Latest SEC Filings
Name
KURA's Discussions on Twitter

Compare KURA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KURA
Kura Oncology Inc
7.65 649.24M 0 -168.09M -138.01M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-06-25 Downgrade BTIG Research Buy → Neutral
Oct-24-24 Initiated UBS Buy
Oct-14-24 Downgrade Stifel Buy → Hold
Dec-22-23 Initiated Mizuho Buy
Aug-11-23 Initiated BofA Securities Buy
Jul-27-23 Initiated Scotiabank Sector Perform
May-17-23 Initiated BTIG Research Buy
Jan-31-23 Initiated Stifel Buy
Jul-12-22 Initiated Cantor Fitzgerald Overweight
Feb-15-22 Initiated Jefferies Buy
May-05-21 Resumed Credit Suisse Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Dec-07-20 Reiterated H.C. Wainwright Buy
Dec-03-20 Initiated Stifel Buy
Nov-05-20 Downgrade Piper Sandler Overweight → Neutral
Jul-07-20 Initiated Credit Suisse Outperform
May-05-20 Initiated Barclays Overweight
Jul-18-19 Initiated Deutsche Bank Buy
Nov-09-18 Initiated Piper Jaffray Overweight
Aug-01-18 Initiated H.C. Wainwright Buy
Oct-13-16 Resumed Leerink Partners Outperform
Jan-22-16 Initiated JMP Securities Mkt Outperform
Dec-30-15 Initiated Oppenheimer Outperform
Dec-16-15 Initiated Citigroup Buy
View All

Kura Oncology Inc Stock (KURA) Latest News

pulisher
Aug 20, 2025

Using RSI to spot recovery in Kura Oncology Inc.Exit Point & Fast Gaining Stock Strategy Reports - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Volume spikes in Kura Oncology Inc. stock – what they meanWeekly Market Summary & Free Safe Entry Trade Signal Reports - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Tools to assess Kura Oncology Inc.’s risk profileWeekly Market Outlook & Weekly High Return Stock Opportunities - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

What data driven models say about Kura Oncology Inc.’s future2025 Year in Review & Risk Managed Investment Entry Signals - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Published on: 2025-08-19 23:46:42 - Newser

Aug 20, 2025
pulisher
Aug 19, 2025

Comparing Kura Oncology Inc. in custom built stock radarsWeekly Investment Recap & Weekly Breakout Stock Alerts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

What does recent volatility data suggest for Kura Oncology Inc.2025 Price Targets & Entry Point Confirmation Alerts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Why Kura Oncology Inc. is moving todayJuly 2025 Institutional & Weekly High Potential Stock Alerts - Newser

Aug 19, 2025
pulisher
Aug 18, 2025

Kura Oncology Inc (KURA Stock: A Sea of Opportunity - investchronicle.com

Aug 18, 2025
pulisher
Aug 18, 2025

Kura Oncology Gains 32%, Insider Trades Reap Benefit - simplywall.st

Aug 18, 2025
pulisher
Aug 18, 2025

Chart based analysis of Kura Oncology Inc. trendsJuly 2025 Retail & Free High Return Stock Watch Alerts - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Analyzing Kura Oncology Inc. with multi timeframe charts2025 Buyback Activity & Target Return Focused Picks - Newser

Aug 18, 2025
pulisher
Aug 17, 2025

What high frequency data says about Kura Oncology Inc.2025 Major Catalysts & Safe Capital Growth Trade Ideas - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Order flow analysis tools used on Kura Oncology Inc.Earnings Risk Summary & Real-Time Volume Analysis Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Kura Oncology (NASDAQ:KURA) Shares Gap Up – Still a Buy? - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

Is Kura Oncology Inc. stock entering bullish territoryTreasury Yields & Long-Term Growth Plans - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Wall Street Zen Upgrades Kura Oncology (NASDAQ:KURA) to “Hold” - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

Using Bollinger Bands to evaluate Kura Oncology Inc.July 2025 Retail & AI Forecasted Entry and Exit Points - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

What makes Kura Oncology Inc. stock price move sharply2025 Macro Impact & Weekly Watchlist for Consistent Profits - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

CEO Buy-In and Analyst Optimism at Kura Oncology: A Strategic Opportunity in Oncology Innovation - AInvest

Aug 16, 2025
pulisher
Aug 15, 2025

Quant Strategy Flags Kura Oncology Inc. for EntryMarket Performance Recap & Safe Swing Trade Setup Alerts - metal.it

Aug 15, 2025
pulisher
Aug 15, 2025

How hedge fund analytics apply to Kura Oncology Inc. stockMarket Trend Report & Verified Stock Trade Ideas - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Kura Oncology Inc. stock chart pattern explainedJuly 2025 Final Week & AI Driven Stock Movement Reports - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Kura Oncology Shares Rise After CEO Buys Company Shares - MarketScreener

Aug 15, 2025
pulisher
Aug 15, 2025

Why Kura Oncology (KURA.O) Spiked 14% on a Quiet Day — A Technical Deep Dive - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Kura Oncology Surges 13.18%—What's Really Behind the Intraday Move? - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Multi asset correlation models including Kura Oncology Inc.July 2025 Sector Moves & Daily Volume Surge Signals - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

US Bancorp DE Acquires 17,523 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World

Aug 15, 2025
pulisher
Aug 14, 2025

Kura Oncology’s CEO Makes a Bold Move with Significant Stock Purchase - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Price Consolidation Hints at Upcoming Move in Kura Oncology Inc.2025 Fundamental Recap & Weekly Setup with ROI Potential - 선데이타임즈

Aug 14, 2025
pulisher
Aug 13, 2025

JMP Securities Lowers Kura Oncology Price Target to $24, Maintains Market Outperform Rating - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Analysts Weigh In on 10x Genomics, Kura Oncology and Insulet: Buy or Hold? - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

JMP Securities Has Lowered Expectations for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World

Aug 13, 2025
pulisher
Aug 12, 2025

Kura Oncology’s Earnings Call: Progress Amidst Challenges - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

Kura Oncology, Inc. (NASDAQ:KURA) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 12, 2025
pulisher
Aug 12, 2025

Why Kura Oncology Inc. stock attracts strong analyst attentionDouble in 10 Days Stock Ideas - newsyoung.net

Aug 12, 2025
pulisher
Aug 12, 2025

Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook - Investing.com

Aug 12, 2025
pulisher
Aug 12, 2025

Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook By Investing.com - Investing.com Nigeria

Aug 12, 2025
pulisher
Aug 12, 2025

Wedbush Has Bearish Forecast for Kura Oncology Q1 Earnings - Defense World

Aug 12, 2025
pulisher
Aug 12, 2025

Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Aug 12, 2025
pulisher
Aug 11, 2025

JMP Securities Maintains Market Outperform on Kura Oncology with New PT of $24 - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Kura Oncology stock price target lowered to $24 at Citizens JMP - Investing.com Canada

Aug 11, 2025
pulisher
Aug 11, 2025

What candlestick patterns are forming on Kura Oncology Inc.Free Pattern Detection for Entry Confirmation - Newser

Aug 11, 2025
pulisher
Aug 10, 2025

Kura Oncology price target lowered to $27 from $29 at BofA - TipRanks

Aug 10, 2025
pulisher
Aug 10, 2025

Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance

Aug 10, 2025
pulisher
Aug 09, 2025

Kura Oncology Reports Q2 2025 Earnings: Key Takeaways - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Candlestick Reversal Detected on Kura Oncology Inc.’s ChartStrong Buy With Technical Confidence Supported - beatles.ru

Aug 09, 2025
pulisher
Aug 08, 2025

How to escape a deep drawdown in Kura Oncology Inc.Market Downturn Defense Strategy Analysis - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Kura Oncology shares fall 5.12% intraday despite FDA Priority Review of ziftomenib NDA. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Kura Oncology’s Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Earnings call transcript: Kura Oncology Q2 2025 shows revenue miss, EPS below forecast By Investing.com - Investing.com South Africa

Aug 08, 2025

Kura Oncology Inc Stock (KURA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Kura Oncology Inc Stock (KURA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
WILSON TROY EDWARD
President and CEO
Aug 13 '25
Buy
6.64
13,494
89,623
50,968
Bair Teresa Brophy
Chief Legal Officer
May 19 '25
Sale
5.96
1,559
9,292
107,948
FORD KATHLEEN
Chief Operating Officer
May 19 '25
Sale
6.28
1,558
9,777
21,367
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):